NONALCOHOLIC STEATOHEPATITIS
Clinical trials for NONALCOHOLIC STEATOHEPATITIS explained in plain language.
Never miss a new study
Get alerted when new NONALCOHOLIC STEATOHEPATITIS trials appear
Sign up with your email to follow new studies for NONALCOHOLIC STEATOHEPATITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo aims to reverse liver scarring in NASH cirrhosis
Disease control CompletedThis study tested two drugs—semaglutide and a combination of cilofexor and firsocostat—alone and together in 457 people with cirrhosis from NASH. The goal was to see if these treatments could improve liver scarring without worsening the disease. Results will show whether these dr…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 24, 2026 00:04 UTC
-
New shot targets genetic form of fatty liver disease
Disease control CompletedThis study tested a monthly injection called AZD2693 in 220 adults with non-alcoholic steatohepatitis (NASH) and liver scarring, who carry a specific genetic risk factor. The goal was to see if the drug could reverse liver inflammation and scarring without making it worse. The tr…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 24, 2026 00:03 UTC
-
New pill HPG1860 shows promise for fatty liver disease in early trial
Disease control CompletedThis Phase 2a trial tested three different doses of an oral drug called HPG1860 against a placebo in 89 adults with NASH, a serious fatty liver disease. The main goals were to check safety and see if the drug could reduce liver fat over 12 weeks. Results are complete, but the stu…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Hepagene (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 24, 2026 00:01 UTC
-
New drug shows promise against fatty liver disease in major trial
Disease control CompletedThis study tested an experimental drug called efinopegdutide in 381 adults with non-alcoholic steatohepatitis (NASH), a serious form of fatty liver disease. The main goal was to see if the drug could help the liver heal (resolve NASH) without making scarring worse. Participants r…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 22, 2026 12:09 UTC
-
Massive study tracks fatty liver disease patients to uncover Real-World treatment patterns
Knowledge-focused CompletedThis study followed over 7,300 people with nonalcoholic fatty liver disease (NAFLD) and its more severe form, NASH, in regular doctor visits. Researchers aimed to understand how the disease progresses and what treatments doctors are using, since no drugs are officially approved f…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Sponsor: Target PharmaSolutions, Inc. • Aim: Knowledge-focused
Last updated Jun 17, 2026 12:07 UTC